Eric J. Tarcha

1.0k total citations
25 papers, 693 citations indexed

About

Eric J. Tarcha is a scholar working on Molecular Biology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Eric J. Tarcha has authored 25 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Epidemiology and 7 papers in Infectious Diseases. Recurrent topics in Eric J. Tarcha's work include Fungal Infections and Studies (7 papers), Antifungal resistance and susceptibility (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Eric J. Tarcha is often cited by papers focused on Fungal Infections and Studies (7 papers), Antifungal resistance and susceptibility (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Eric J. Tarcha collaborates with scholars based in United States, Australia and Netherlands. Eric J. Tarcha's co-authors include Garry T. Cole, Shawn P. Iadonato, Chiung-Yu Hung, Venkatesha Basrur, Malcolm J. Gardner, Ernesto J. Muñoz‐Elías, Roger A. Herr, D. W. Peckham, Peter Probst and Christine Beeton and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and PLoS ONE.

In The Last Decade

Eric J. Tarcha

23 papers receiving 677 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric J. Tarcha United States 10 311 265 192 103 97 25 693
Roger A. Herr United States 13 410 1.3× 406 1.5× 150 0.8× 48 0.5× 135 1.4× 19 896
Ann Schlesinger United States 6 638 2.1× 184 0.7× 151 0.8× 71 0.7× 451 4.6× 6 1.3k
Jacob Souopgui Belgium 17 732 2.4× 71 0.3× 289 1.5× 110 1.1× 127 1.3× 61 1.2k
Michelle E. Maxson Canada 16 308 1.0× 242 0.9× 213 1.1× 139 1.3× 93 1.0× 23 785
Melanie Ulrich United States 15 300 1.0× 126 0.5× 110 0.6× 61 0.6× 35 0.4× 22 666
Kristin A. Trott United States 8 257 0.8× 283 1.1× 91 0.5× 66 0.6× 82 0.8× 10 623
Matthew R. Digby Australia 16 262 0.8× 91 0.3× 49 0.3× 123 1.2× 174 1.8× 23 711
J.S. Ryerse United States 13 501 1.6× 76 0.3× 102 0.5× 342 3.3× 66 0.7× 23 822
Olof Karlberg Sweden 13 613 2.0× 36 0.1× 43 0.2× 121 1.2× 57 0.6× 17 889
Melisa Gualdrón‐López Belgium 19 550 1.8× 607 2.3× 62 0.3× 31 0.3× 98 1.0× 32 1.0k

Countries citing papers authored by Eric J. Tarcha

Since Specialization
Citations

This map shows the geographic impact of Eric J. Tarcha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Tarcha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Tarcha more than expected).

Fields of papers citing papers by Eric J. Tarcha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric J. Tarcha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Tarcha. The network helps show where Eric J. Tarcha may publish in the future.

Co-authorship network of co-authors of Eric J. Tarcha

This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Tarcha. A scholar is included among the top collaborators of Eric J. Tarcha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric J. Tarcha. Eric J. Tarcha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stepanyuk, Galina A., David F. Thieker, Kui K. Chan, et al.. (2024). Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation. Molecular Therapy — Methods & Clinical Development. 32(3). 101301–101301. 1 indexed citations
2.
Stegeman, Coen A., Ernesto J. Muñoz‐Elías, Eric J. Tarcha, et al.. (2023). Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitis. Lara D. Veeken. 63(1). 198–208. 5 indexed citations
3.
Cashman, Kathleen A., Eric R. Wilkinson, Jeff Posakony, et al.. (2022). Lassa antiviral LHF-535 protects guinea pigs from lethal challenge. Scientific Reports. 12(1). 19911–19911. 8 indexed citations
4.
Amberg, Sean M., et al.. (2022). Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults. Antimicrobial Agents and Chemotherapy. 66(11). e0095122–e0095122. 8 indexed citations
5.
Guillaudeux, Thierry, Eric J. Tarcha, Nathan Eyde, et al.. (2021). Abstract 1637: A fully human anti-vista antibody as a promising therapy against poorly immunogenic tumors. Cancer Research. 81(13_Supplement). 1637–1637. 3 indexed citations
6.
Guillaudeux, Thierry, et al.. (2021). 879 A promising cancer immunotherapy target: novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27. SHILAP Revista de lepidopterología. A921–A921. 1 indexed citations
7.
Guillaudeux, Thierry, et al.. (2021). 268 KVA 12.1 a novel fully human anti-VISTA antibody: clinical trial design in monotherapy and in combination with an anti-PD1 antibody. Regular and Young Investigator Award Abstracts. A291–A291. 8 indexed citations
8.
Land, J. A., Coen A. Stegeman, Ernesto J. Muñoz‐Elías, et al.. (2017). Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis. Frontiers in Immunology. 8. 1205–1205. 14 indexed citations
9.
Olsen, Christine, et al.. (2017). 695 Topical application of KPI-150, a potent inhibitor of Kv1.3 channels on effector memory T cells, demonstrates preclinical efficacy in atopic dermatitis model. Journal of Investigative Dermatology. 137(5). S119–S119. 1 indexed citations
10.
Tarcha, Eric J., et al.. (2017). Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial. PLoS ONE. 12(7). e0180762–e0180762. 123 indexed citations
11.
Olsen, Catharina, Eric J. Tarcha, Peter Probst, D. W. Peckham, & Shawn P. Iadonato. (2016). LB779 Dalazatide (ShK-186), a first-in-class peptide inhibitor of Kv1.3 potassium channels, demonstrates safety, tolerability and proof of concept of efficacy in patients with active plaque psoriasis. Journal of Investigative Dermatology. 136(8). B5–B5. 4 indexed citations
12.
Mercado, Jose, Mingming Xu, Kevin Norton, et al.. (2016). (421) A novel, non-opioid, conesnail peptide-based analgesic as a therapeutic alternative for the treatment of chronic pain. Journal of Pain. 17(4). S79–S80. 1 indexed citations
13.
Muñoz‐Elías, Ernesto J., D. W. Peckham, Eric J. Tarcha, et al.. (2014). Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis.. Data Archiving and Networked Services (DANS). 66. 1 indexed citations
14.
Tarcha, Eric J., Luz M. Londono, Amy Banks, et al.. (2012). Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease (51.5). The Journal of Immunology. 188(1_Supplement). 51.5–51.5. 1 indexed citations
15.
Beeton, Christine, K. George Chandy, Shawn P. Iadonato, Ernesto J. Muñoz‐Elías, & Eric J. Tarcha. (2012). 38. Development of the Sea Anemone Toxin ShK-186 for the Treatment of Autoimmune Diseases: PK and ADME Perspectives. Toxicon. 60(2). 114–114. 1 indexed citations
16.
Chi, Victor, Michael W. Pennington, Raymond S. Norton, et al.. (2011). Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon. 59(4). 529–546. 171 indexed citations
17.
Bedard, Kristin, et al.. (2010). Small Molecule Agonists of the RIG-I Pathway and their Potent Antiviral Actions. Antiviral Research. 86(1). A25–A25. 1 indexed citations
18.
Tarcha, Eric J., Venkatesha Basrur, Chiung-Yu Hung, Malcolm J. Gardner, & Garry T. Cole. (2005). A Recombinant Aspartyl Protease ofCoccidioides posadasiiInduces Protection against Pulmonary Coccidioidomycosis in Mice. Infection and Immunity. 74(1). 516–527. 56 indexed citations
19.
Hung, Chiung-Yu, et al.. (2004). Profiling gene expression inCoccidioides posadasii. Medical Mycology. 42(1). 59–71. 15 indexed citations
20.
Cole, Garry T., Jianmin Xue, C. N. Okeke, et al.. (2004). Prospects of vaccines for medically important fungi† A vaccine against coccidioidomycosis is justified and attainable. Medical Mycology. 42(3). 189–216. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roger A. Herr Breakdown of academic impact, for papers by Ann Schlesinger Breakdown of academic impact, for papers by Jacob Souopgui Breakdown of academic impact, for papers by Michelle E. Maxson Breakdown of academic impact, for papers by Melanie Ulrich Breakdown of academic impact, for papers by Kristin A. Trott Breakdown of academic impact, for papers by Matthew R. Digby Breakdown of academic impact, for papers by J.S. Ryerse Breakdown of academic impact, for papers by Olof Karlberg Breakdown of academic impact, for papers by Melisa Gualdrón‐López
Rankless by CCL
2026